138 related articles for article (PubMed ID: 16406421)
1. CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women.
Ribeiro FS; de Amorim LM; de Almeida Simão T; Mendonça GA; de Moura Gallo CV; Pinto LF
Toxicol Lett; 2006 Jun; 164(1):90-5. PubMed ID: 16406421
[TBL] [Abstract][Full Text] [Related]
2. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.
Kim JY; Lee CS; Kim HO; Jo YH; Lee J; Jung MH; Baik HH; Choe W; Kang I; Yoon KS
Oncol Rep; 2009 Sep; 22(3):487-92. PubMed ID: 19639193
[TBL] [Abstract][Full Text] [Related]
3. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Ohtake N; Takei T; Nakata S; Hasumi M; Yamanaka H
Anticancer Res; 2003; 23(6D):4941-6. PubMed ID: 14981949
[TBL] [Abstract][Full Text] [Related]
4. A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides.
Dialyna I; Tzanakakis G; Dolapsakis G; Tsatsakis A
Toxicol Lett; 2004 Jun; 151(1):267-71. PubMed ID: 15177662
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
[TBL] [Abstract][Full Text] [Related]
6. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
[TBL] [Abstract][Full Text] [Related]
7. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.
Haiman CA; Stram DO; Pike MC; Kolonel LN; Burtt NP; Altshuler D; Hirschhorn J; Henderson BE
Hum Mol Genet; 2003 Oct; 12(20):2679-92. PubMed ID: 12944421
[TBL] [Abstract][Full Text] [Related]
9. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.
Hirose K; Matsuo K; Toyama T; Iwata H; Hamajima N; Tajima K
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1407-11. PubMed ID: 15298966
[TBL] [Abstract][Full Text] [Related]
10. Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women.
Dick IM; Devine A; Prince RL
Am J Physiol Endocrinol Metab; 2005 May; 288(5):E989-95. PubMed ID: 15613678
[TBL] [Abstract][Full Text] [Related]
11. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women.
Baghaei F; Rosmond R; Westberg L; Hellstrand M; Eriksson E; Holm G; Björntorp P
Obes Res; 2003 Apr; 11(4):578-85. PubMed ID: 12690088
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility.
Wu MH; Chou YC; Yu CP; Yang T; You SL; Chen CJ; Sun CA
Eur J Cancer Prev; 2008 Aug; 17(4):317-22. PubMed ID: 18562955
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants of CYP19 (aromatase) and breast cancer risk.
Kristensen VN; Harada N; Yoshimura N; Haraldsen E; Lonning PE; Erikstein B; Kåresen R; Kristensen T; Børresen-Dale AL
Oncogene; 2000 Mar; 19(10):1329-33. PubMed ID: 10713674
[TBL] [Abstract][Full Text] [Related]
14. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk.
Zheng W; Gao YT; Shu XO; Wen W; Cai Q; Dai Q; Smith JR
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):709-14. PubMed ID: 15159300
[TBL] [Abstract][Full Text] [Related]
15. CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype.
Xita N; Lazaros L; Georgiou I; Tsatsoulis A
Fertil Steril; 2010 Jun; 94(1):250-4. PubMed ID: 19324338
[TBL] [Abstract][Full Text] [Related]
16. Associations between androgen and Vitamin D receptor microsatellites and postmenopausal breast cancer.
Wedrén S; Magnusson C; Humphreys K; Melhus H; Kindmark A; Stiger F; Branting M; Persson I; Baron J; Weiderpass E
Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1775-83. PubMed ID: 17855696
[TBL] [Abstract][Full Text] [Related]
17. The (TTTA)n polymorphism of aromatase (CYP19) gene is associated with age at menarche.
Xita N; Chatzikyriakidou A; Stavrou I; Zois Ch; Georgiou I; Tsatsoulis A
Hum Reprod; 2010 Dec; 25(12):3129-33. PubMed ID: 20937744
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.
Healey CS; Dunning AM; Durocher F; Teare D; Pharoah PD; Luben RN; Easton DF; Ponder BA
Carcinogenesis; 2000 Feb; 21(2):189-93. PubMed ID: 10657957
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic variation in CYP19 and the risk of breast cancer.
Baxter SW; Choong DY; Eccles DM; Campbell IG
Carcinogenesis; 2001 Feb; 22(2):347-9. PubMed ID: 11181459
[TBL] [Abstract][Full Text] [Related]
20. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
